Proactive Investors
11 Jul 2026, 09:46 UTC · 2h ago
Futura Medical: US Eroxon deal and WSD4000 breakthrough - ICYMI
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
11 Jul 2026, 09:46 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Futura Medical's WSD4000 candidate showed statistically significant improvement over placebo in a study for female sexual dysfunction. — Positive clinical data significantly de-risks the asset and increases the probability of success for the upcoming Phase 3 trial.
+0.60Futura Medical has entered a US commercial partnership with Market Performance Group (MPG) for its product Eroxon. — Partnering with an experienced US consumer healthcare firm provides the distribution and marketing infrastructure needed to scale revenue.
+0.40Eroxon is currently generating approximately $5 million in trade-level sales in the US. — Provides a concrete baseline of market traction and revenue for the product's commercial viability.
+0.30Continue reading
6 related stories
Top 2 movers · tap to explore
The company plans to launch WSD4000 in the US and Europe by early 2028, pending the completion of a Phase 3 clinical program. — Sets a clear timeline for future commercialization and potential revenue growth, though it remains subject to funding and trial results.
+0.20Which stocks this story touches
The company reported a new US commercial partnership for Eroxon and positive clinical data for WSD4000 which de-risks the upcoming Phase 3 trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
20h ago
